Managing Complex Biomarker Data

Discussions were lively at the “Digitization of Clinical Development & Clinical Trials” symposium at last week’s Bio-IT World conference. Addressing an audience of biotech and pharma IT and data leaders, QuartzBio’s Tobi Guennel gave a provocative presentation on how deploying generative AI can amplify the ability of precision medicine approaches to accelerate drug development. Read More →

QuartzBio’s team has deep experience in technology-enabled solutions for the life science industry. In this blog series, we invited you to get to know a member of the QuartzBio team.

This month, we are delighted to talk with Caitlin Cook, QuartzBio’s Director, Customer Success. After learning about Caitlin here, please feel free to connect with her on LinkedIn.

1. In your own words, what do you do?
   Modern drug development is a collaborative process involving a multitude of stakeholders - from scientists and researchers to data analysts and regulatory professionals. My team’s role is to Read More →

Join Bill Hall for a webinar demo of the QuartzBio® enterprise Biomarker Data Management solution. We'll show you how to generate patient profiles to view tumor burden over course of treatment, explore multi-marker views of patient profiles, and cross-reference biomarker measures across file types. Read More →

AI/ML can be a powerful, error-reducing tool for managing clinical sample data as well as biomarker data. AI/ML-based tools should not replace human judgment, particularly for insight generation, at least until AI/ML-based tools are extensively and rigorously validated (as any piece of critical software would be). Furthermore, regulatory compliance and data privacy are of utmost importance and must be considered when building and using solutions that leverage generative AI frameworks. However, near-term applications of AI/ML can dramatically improve any tedious process involving a human inspecting data. We list some of these processes in the box below, along with steps we Read More →